Abstract
Introduction
Thyroid cancer (TC), follicular adenoma (FA) and Hashimoto’s thyroiditis (HT) are three of the most frequently reported abnormalities that affect the thyroid gland. A frequent co-occurrence along with similar histopathological features is observed between TC and FA as well as between TC and HT. The conventional diagnostic methods such as histochemical analysis present complications in differential diagnosis when these abnormalities occur simultaneously. Hence, the authors recognize novel methods based on screening genetic defects of thyroid abnormalities as viable diagnostic and prognostic methods that could complement the conventional methods.
Methods
We have extensively reviewed the existing literature on TC, FA and HT and also on three genes, namely braf, nras and ret/ptc, that could be used to differentially diagnose the three abnormalities. Emphasis was also given to the screening methods available to detect the said molecular markers.
Results and conclusion
It can be conferred from the analysis of the available data that the utilization of braf, nras and ret/ptc as markers for the therapeutic evaluation of FA and HT is debatable. However, molecular screening for braf, nras and ret/ptc mutations proves to be a conclusive method that could be employed to differentially diagnose TC from HT and FA in the instance of a suspected co-occurrence. Thyroid cancer patients can be highly benefited from the screening for the said genetic markers, especially the braf gene due to its diagnostic value as well as due to the availability of personalized medicine targeted specifically for braf mutants.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahlawat S, Sharma R, Maitra A et al (2014) Designing, optimization and validation of tetra-primer ARMS PCR protocol for genotyping mutations in caprine Fec genes. Meta Gene 2:439–449. doi:10.1016/j.mgene.2014.05.004
Akamizu T, Amino N, DeGroot LJ (2013) Hashimoto’s thyroiditis. MDText.com Inc, South Dartmouth
Ali SM, He J, Carson W et al (2014) Extended antitumor response of a BRAF V600E papillary thyroid carcinoma to vemurafenib. Case Rep Oncol 7:343–348. doi:10.1159/000363377
Al-Sobhi S, Clark O (2001) Thyroid carcinosarcoma and undifferentiated thyroid carcinoma. In: Holzheimer RG, Mannick JA (eds) Surgical Treatment: Evidence-Based and Problem-Oriented. Zuckschwerdt, Munich
Arcaini L, Zibellini S, Boveri E et al (2012) The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 119:188–191. doi:10.1182/blood-2011-08-368209
Arif S, Blanes A, Diaz-Cano SJ (2002) Hashimoto’s thyroiditis shares features with early papillary thyroid carcinoma. Histopathology 41:357–362. doi:10.1046/j.1365-2559.2002.01467.x
Ashida A, Sakaizawa K, Mikoshiba A et al (2016) Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR. Int J Clin Oncol. doi:10.1007/s10147-016-0976-y
Bae J-S, Choi SK, Jeon S et al (2014) Impact of NRAS mutations on the diagnosis of follicular neoplasm of the thyroid. Int J Endocrinol 2014:289834. doi:10.1155/2014/289834
Barbano R, Pasculli B, Coco M et al (2015) Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients. Sci Rep 5:18592. doi:10.1038/srep18592
Barbano R, Pasculli B, Coco M et al (2016) Evaluation of pre-analytical procedures for the detection of BRAF V600 mutations in melanoma patients: comparison between Sanger sequencing and Competitive allele-specific TaqMan PCR (Cast-PCR). Eur J Cancer 61:S127–S128. doi:10.1016/S0959-8049(16)61452-1
Barras D (2015) BRAF mutation in colorectal cancer: an update. Biomark Cancer 7:9–12. doi:10.4137/BIC.S25248
Benlloch S, Payá A, Alenda C et al (2006) Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn 8:540–543. doi:10.2353/jmoldx.2006.060070
Brahma B, Yulian ED, Ramli M et al (2012) 44. Surgical perspective of T1799a BRAF mutation diagnostic value in papillary thyroid carcinoma. Eur J Surg Oncol 38:745. doi:10.1016/j.ejso.2012.06.045
Cantwell-Dorris ER, O’Leary JJ, Sheils OM (2011) BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 10:385–394. doi:10.1158/1535-7163.MCT-10-0799
Cheng S-P, Hsu Y-C, Liu C-L et al (2014) Significance of allelic percentage of BRAF c.1799T>A (V600E) mutation in papillary thyroid carcinoma. Ann Surg Oncol 21(Suppl 4):S619–S626. doi:10.1245/s10434-014-3723-5
Cheung CC, Ezzat S, Freeman JL et al (2001) Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14:338–342. doi:10.1038/modpathol.3880312
Chung K, Yang SK, Lee GK et al (2006) Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol 65:660–666. doi:10.1111/j.1365-2265.2006.02646.x
Colato C, Vicentini C, Cantara S et al (2015) Break-apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangements. Eur J Endocrinol 172:571–582. doi:10.1530/EJE-14-0930
Dailey ME, Lindsay S, Skahen R (1955) Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 70:291–297. doi:10.1001/archsurg.1955.01270080137023
Didelot A, Le Corre D, Luscan A et al (2012) Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol 92:275–280. doi:10.1016/j.yexmp.2012.03.001
Eischeid AC (2011) SYTO dyes and EvaGreen outperform SYBR Green in real-time PCR. BMC Res Notes 4:263. doi:10.1186/1756-0500-4-263
Elisei R, Romei C, Vorontsova T et al (2001) RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab 86:3211–3216. doi:10.1210/jcem.86.7.7678
Fagin JA (2005) Genetics of papillary thyroid cancer initiation: implications for therapy. Trans Am Clin Climatol Assoc 116:259–269 (discussion 269–271)
Faquin WC (2008) Recurring problems in histologic and cytologic evaluation. Arch Pathol Lab Med 132:622–632
Fernández-Medarde A, Santos E (2011) Ras in cancer and developmental diseases. Genes Cancer 2:344–358. doi:10.1177/1947601911411084
Fischer AH, Bond JA, Taysavang P et al (1998) Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. Am J Pathol 153:1443–1450. doi:10.1016/S0002-9440(10)65731-8
Gómez Sáez JM (2011) Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genom 12:597–608. doi:10.2174/138920211798120826
Goodsell DS (1999) The molecular perspective: the ras oncogene. Oncologist 4:263–264
Guerra A, Marotta V, Sapio MR, Vitale M (2011a) RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol 165:499–507. doi:10.1530/eje-11-0499
Guerra A, Sapio MR, Marotta V et al (2011b) Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr J 58:31–38. doi:10.1507/endocrj.K10E-260
Howell GM, Hodak SP, Yip L (2013) RAS mutations in thyroid cancer. Oncologist 18:926–932. doi:10.1634/theoncologist.2013-0072
Huang T, Zhuge J, Zhang WW (2013) Sensitive detection of BRAF V600E mutation by amplification refractory mutation system (ARMS)-PCR. Biomark Res 1:3. doi:10.1186/2050-7771-1-3
Ilie MI, Lassalle S, Long-Mira E et al (2014) Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Thyroid 24:858–866. doi:10.1089/thy.2013.0302
Jankovic B, Le KT, Hershman JM (2013) Clinical Review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab 98:474–482. doi:10.1210/jc.2012-2978
Kebebew E, Weng J, Bauer J et al (2007) The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466–470. doi:10.1097/SLA.0b013e318148563d (discussion 470–471)
Li F, Feng Y, Fang R et al (2012a) Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. Cell Res 22:928–931. doi:10.1038/cr.2012.27
Li Y, Zhou G, Ozaki T et al (2012b) Distinct histopathological features of Hashimoto’s thyroiditis with respect to IgG4-related disease. Mod Pathol 25:1086–1097. doi:10.1038/modpathol.2012.68
Liu H, Lin F (2015) Application of immunohistochemistry in thyroid pathology. Arch Pathol Lab Med 139:67–82. doi:10.5858/arpa.2014-0056-RA
LiVolsi VA (2011) Papillary thyroid carcinoma: an update. Mod Pathol 24(Suppl 2):S1–S9. doi:10.1038/modpathol.2010.129
Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J (2013) Molecular cell biology, 7th edn. Freeman & Co, New York
Mahdieh N, Rabbani B (2013) An overview of mutation detection methods in genetic disorders. Iran J Pediatr 23:375–388
McHenry CR, Phitayakorn R (2011) Follicular adenoma and carcinoma of the thyroid gland. Oncologist 16:585–593. doi:10.1634/theoncologist.2010-0405
Medrano RFV, de Oliveira CA (2014) Guidelines for the tetra-primer ARMS-PCR technique development. Mol Biotechnol 56:599–608. doi:10.1007/s12033-014-9734-4
Müller S, Matthiesen SH, Nielsen KV (2009) Preparation of FFPE tissue slides for solid tumor FISH analysis. In: Kumar GL, Rudbeck L (eds) Education Guide: Immunohistochemical Staining Methods. 5th edn. Dako North America, Carpinteria, CA, pp 67–73
Nei M, Nozawa M (2011) Roles of mutation and selection in speciation: from Hugo de Vries to the modern genomic era. Genom Biol Evol 3:812–829. doi:10.1093/gbe/evr028
Nikiforov YE (2002) RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13:3–16. doi:10.1385/EP:13:1:03
Nikiforov YE (2011) Molecular analysis of thyroid tumors. Mod Pathol 24:S34–S43. doi:10.1038/modpathol.2010.167
Nikiforov YE, Koshoffer A, Nikiforova M et al (1999) Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene 18:6330–6334. doi:10.1038/sj.onc.1203019
Nikiforova MN, Caudill CM, Biddinger P, Nikiforov YE (2002) Prevalence of RET/PTC rearrangements in Hashimoto’s thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol 10:15–22. doi:10.1177/106689690201000104
Nollau P, Wagener C (1997) Methods for detection of point mutations: performance and quality assessment. Clin Chem 43:1114–1128
Pacini F, Castagna MG, Brilli L, Pentheroudakis G (2010) Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v214–v219. doi:10.1093/annonc/mdq190
Pellegriti G, Frasca F, Regalbuto C et al (2013) Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013:965212. doi:10.1155/2013/965212
Pisarchik AV, Ermak G, Fomicheva V et al (1998) The ret/PTC1 rearrangement is a common feature of Chernobyl-associated papillary thyroid carcinomas from Belarus. Thyroid 8:133–139. doi:10.1089/thy.1998.8.133
Prior IA, Lewis PD, Mattos C (2012) A comprehensive survey of Ras mutations in cancer. Cancer Res 72:2457–2467. doi:10.1158/0008-5472.CAN-11-2612
Procop GW (2007) Molecular diagnostics for the detection and characterization of microbial pathogens. Clin Infect Dis 45:S99–S111. doi:10.1086/519259
Rabes HM (2001) Gene rearrangements in radiation-induced thyroid carcinogenesis. Med Pediatr Oncol 36:574–582. doi:10.1002/mpo.1133
Rajalingam K, Schreck R, Rapp UR, Albert Š (2007) Ras oncogenes and their downstream targets. Biochim Biophys Acta Mol Cell Res 1773:1177–1195. doi:10.1016/j.bbamcr.2007.01.012
Rasmussen HB (2012) Restriction fragment length polymorphism analysis of PCR-amplified fragments (PCR-RFLP) and gel electrophoresis—valuable tool for genotyping and genetic fingerprinting. Gel Electrophor Princ Basics. doi:10.5772/37724
Repplinger D, Bargren A, Zhang Y-W et al (2008) Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 150:49–52. doi:10.1016/j.jss.2007.09.020
Rhoden KJ, Johnson C, Brandao G et al (2004) Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Lab Invest 84:1557–1570. doi:10.1038/labinvest.3700198
Rivera M, Ricarte-Filho J, Knauf J et al (2010) Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23:1191–1200. doi:10.1038/modpathol.2010.112
Romei C, Elisei R (2012) RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma. Front Endocrinol 3:54. doi:10.3389/fendo.2012.00054
Romei C, Ciampi R, Faviana P et al (2008) BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 15:511–520. doi:10.1677/ERC-07-0130
Sadow PM, Heinrich MC, Corless CL et al (2010) Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. Endocr Pathol 21:73–79. doi:10.1007/s12022-009-9101-3
Santoro M, Melillo RM, Fusco A (2006) RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol 155:645–653. doi:10.1530/eje.1.02289
Sariola H, Saarma M (2003) Novel functions and signalling pathways for GDNF. J Cell Sci 116:3855–3862. doi:10.1242/jcs.00786
Tajadini M, Panjehpour M, Javanmard SH (2014) Comparison of SYBR Green and TaqMan methods in quantitative real-time polymerase chain reaction analysis of four adenosine receptor subtypes. Adv Biomed Res 3:85. doi:10.4103/2277-9175.127998
Talmaci R, Traeger-Synodinos J, Kanavakis E et al (2004) Scanning of β-globin gene for identification of β-thalassemia mutation in Romanian population. J Cell Mol Med 8:232–240. doi:10.1111/j.1582-4934.2004.tb00278.x
Tomei S, Bedognetti D, De Giorgi V et al (2015) The immune-related role of BRAF in melanoma. Mol Oncol 9:93–104. doi:10.1016/j.molonc.2014.07.014
Troggio M, Malacarne G, Vezzulli S et al (2008) Comparison of different methods for SNP detection in grapevine. Vitis - J Grapevine Res 47:21–30
Vasko VV, Gaudart J, Allasia C et al (2004) Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. Eur J Endocrinol 151:779–786. doi:10.1530/eje.0.1510779
Worden F (2014) Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol 6:267–279. doi:10.1177/1758834014548188
Xing M, Westra WH, Tufano RP et al (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373–6379. doi:10.1210/jc.2005-0987
Zaletel K (2007) Determinants of thyroid autoantibody production in Hashimoto’s thyroiditis. Expert Rev Clin Immunol 3:217–223. doi:10.1586/1744666X.3.2.217
Zaletel K, Gaberšček S (2011) Hashimoto’s thyroiditis: from genes to the disease. Curr Genomics 12:576–588. doi:10.2174/138920211798120763
Zatelli MC, Trasforini G, Leoni S et al (2009) BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 161:467–473. doi:10.1530/EJE-09-0353
Zeng R-C, Jin L-P, Chen E-D et al (2016) Potential relationship between Hashimoto’s thyroiditis and BRAF(V600E) mutation status in papillary thyroid cancer. Head Neck 38(Suppl 1):E1019–E1025. doi:10.1002/hed.24149
Zhu Z, Ciampi R, Nikiforova MN et al (2006) Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 91:3603–3610. doi:10.1210/jc.2006-1006
Acknowledgements
The authors would like to recognize and thank Prof. M.V.C. de Silva and Dr. A.A.H. Priyani of the Faculty of Medicine, University of Colombo, for their support and input for this review article and Dr. N.V. Chandrasekharan of the Faculty of Science, University of Colombo.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interests.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Tennakoon, T.M.P.B., Rushdhi, M., Ranasinghe, A.D.C.U. et al. Values of molecular markers in the differential diagnosis of thyroid abnormalities. J Cancer Res Clin Oncol 143, 913–931 (2017). https://doi.org/10.1007/s00432-016-2319-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-016-2319-9